Loading patent…
AssigneeBoard of Regents, The University of Texas System
InventorsWadih Arap, Mikhail G. Kolonin, Paul J. Mintz, Renata Pasqualini, Amado J. Zurita
Estimating the term…
The present invention concerns compositions comprising and methods of identification and use of targeting peptides selective for cancer tissue, particularly prostate or ovarian cancer tissue. The method may comprise identifying endogenous mimeotopes of such peptides, such as GRP78, IL-11Rα and hsp90. Antibodies against such targeting peptides or their mimeotopes may be used for detection, diagnosis and/or staging of prostate or ovarian cancer. In other embodiments, the compositions and methods concern a novel type of gene therapy vector, known as adeno-associated phage (AAP). AAP are of use for targeted delivery of therapeutic agents to particular tissues, organs or cell types, such as prostate or ovarian cancer. In still other embodiments, targeting peptides selective for low-grade lipomas may be used for detection, diagnosis and targeted delivery of therapeutic agents.
An isolated peptide of 50 amino acids or less in size, comprising an IL-11Rα targeting motif having the amino acid sequence of any of SEQ ID NO:5 through SEQ ID NO:29, SEQ ID NO:34, or SEQ ID NO:37, or an isolated peptide of 40 amino acids or less in size comprising an IL-11Rα targeting motif having the amino acid sequence of SEQ ID NO:35, wherein the peptide is conjugated or fused to a second agent.
Dependencies are inferred from the claim text.